MX2011011333A - Composiciones y metodos para tratar la resistencia a la insulina y la diabetes mellituscampo de la invencion. - Google Patents
Composiciones y metodos para tratar la resistencia a la insulina y la diabetes mellituscampo de la invencion.Info
- Publication number
- MX2011011333A MX2011011333A MX2011011333A MX2011011333A MX2011011333A MX 2011011333 A MX2011011333 A MX 2011011333A MX 2011011333 A MX2011011333 A MX 2011011333A MX 2011011333 A MX2011011333 A MX 2011011333A MX 2011011333 A MX2011011333 A MX 2011011333A
- Authority
- MX
- Mexico
- Prior art keywords
- fluids
- electrokinetically
- altered
- membrane
- insulin resistance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Se proporcionan fluidos alterados electrocinéticamente (fluidos electrocinéticos enriquecidos con gas) que comprenden una solución acuosa iónica de nanoestructuras que contienen oxígeno y que tienen carga estabilizada en una cantidad suficiente como para proporcionar la modulación de al menos uno de potencial de membrana celular y conductividad de membrana celular y composiciones y métodos terapéuticos para usarse en el tratamiento de la diabetes y afecciones o trastornos asociados con la diabetes (por ej., resistencia a la insulina) o síntomas de los mismos. Se proporcionan fluidos acuosos iónicos alterados electrocinéticamente opcionalmente en combinación con otros agentes terapéuticos. Aspectos particulares proporcionan la regulación o modulación de transducción de señal intracelular asociada con dichas respuestas inflamatorias por la modulación de al menos uno de membranas celulares, potencial de membrana, proteínas de membrana tales como receptores de membrana, incluyendo pero a modo no taxativo, receptores acoplados a la proteína G (GPCR) y uniones intercelulares (por ej., uniones firmes, uniones de huecos, adherinas de zona y desmasomas) . Otras modalidades incluyen vías de administración o formulaciones particulares para los fluidos alterados electrocinéticamente (por ej., fluidos y soluciones enriquecidos con gas y alterados electrocinéticamente) y composiciones terapéutica:.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17313409P | 2009-04-27 | 2009-04-27 | |
PCT/US2010/032620 WO2010126908A1 (en) | 2009-04-27 | 2010-04-27 | Compositions and methods for treating insulin resistance and diabetes mellitus |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011011333A true MX2011011333A (es) | 2011-11-18 |
Family
ID=43032520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011011333A MX2011011333A (es) | 2009-04-27 | 2010-04-27 | Composiciones y metodos para tratar la resistencia a la insulina y la diabetes mellituscampo de la invencion. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2424507A4 (es) |
JP (2) | JP2012525396A (es) |
CN (1) | CN102413817B (es) |
AU (1) | AU2010241736B2 (es) |
BR (1) | BRPI1013992A2 (es) |
CA (1) | CA2758738A1 (es) |
IL (1) | IL215925A0 (es) |
MX (1) | MX2011011333A (es) |
WO (1) | WO2010126908A1 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
MX2008014024A (es) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Formas poliformas. |
US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
PL2391419T3 (pl) | 2009-01-29 | 2019-12-31 | Forsight Vision4, Inc. | Dostarczanie leku do tylnego odcinka |
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
WO2012019139A1 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
EP3861969A1 (en) | 2010-08-05 | 2021-08-11 | ForSight Vision4, Inc. | Injector apparatus for drug delivery |
SI2600812T1 (sl) | 2010-08-05 | 2021-12-31 | ForSight Vision4, Inc., | Naprava za zdravljenje očesa |
BR112013003110A2 (pt) | 2010-08-12 | 2016-06-28 | Revalesio Corp | composições e métodos para tratamento de taupatia |
MX371198B (es) * | 2010-11-15 | 2020-01-22 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora. |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
CA2818612C (en) | 2010-11-19 | 2020-12-29 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
WO2012142501A1 (en) * | 2011-04-13 | 2012-10-18 | Revalesio Corporation | Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease |
EP4249059A3 (en) | 2011-06-28 | 2023-11-29 | ForSight Vision4, Inc. | An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye |
SI2755600T1 (sl) | 2011-09-16 | 2021-08-31 | Forsight Vision4, Inc. | Naprava za izmenjavo tekočine |
US10010448B2 (en) | 2012-02-03 | 2018-07-03 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
JP6159584B2 (ja) * | 2012-06-14 | 2017-07-05 | 松本 高明 | 輸液、輸液の製造方法および輸液装置 |
CH706747A2 (de) * | 2012-07-17 | 2014-01-31 | Hanspeter Steffen | Verfahren zur Hydration, Straffung und Pflege der Haut, zur Behandlung von Dermatosen, Sonnenbrand und genereller Wunden mit Diamantelektroden hergestelltem Elektrolysewasser. |
GB201300684D0 (en) | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
AU2014236455B2 (en) | 2013-03-14 | 2018-07-12 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
EP4302736A3 (en) | 2013-03-28 | 2024-04-03 | ForSight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
US20170056438A1 (en) * | 2014-10-17 | 2017-03-02 | Aqua Zest Corporation | Nanobubble-containing composition and use thereof |
JP2016063804A (ja) * | 2013-12-27 | 2016-04-28 | 亀井 一郎 | ミトコンドリア活性化組成物 |
US10258503B2 (en) | 2014-07-15 | 2019-04-16 | Forsight Vision4, Inc. | Ocular implant delivery device and method |
MY182793A (en) | 2014-08-08 | 2021-02-05 | Forsight Vision4 Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
US10500091B2 (en) | 2014-11-10 | 2019-12-10 | Forsight Vision4, Inc. | Expandable drug delivery devices and methods of use |
JP6674748B2 (ja) * | 2015-05-27 | 2020-04-01 | 花王株式会社 | Glp−1分泌促進剤 |
CN108430405B (zh) | 2015-11-20 | 2021-04-13 | 弗赛特影像4股份有限公司 | 用于缓释药物递送装置的多孔结构 |
US11617680B2 (en) | 2016-04-05 | 2023-04-04 | Forsight Vision4, Inc. | Implantable ocular drug delivery devices |
CN105878194A (zh) * | 2016-06-07 | 2016-08-24 | 沈阳药科大学 | 一种格列本脲纳米结晶制剂及其制备方法 |
CN106362166B (zh) * | 2016-10-27 | 2019-12-10 | 武汉大学 | 肿瘤坏死因子受体相关泛支架和信号蛋白在治疗脂肪肝和ⅱ型糖尿病中的功能和应用 |
WO2019103906A1 (en) | 2017-11-21 | 2019-05-31 | Forsight Vision4, Inc. | Fluid exchange apparatus for expandable port delivery system and methods of use |
CN110006871A (zh) * | 2019-02-20 | 2019-07-12 | 常州大学 | 一个基于外源性组胺检测的细胞模型以及应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992005792A1 (de) * | 1990-10-02 | 1992-04-16 | Buchholz Klaus L | Verwendung eines reaktionsproduktes aus einem gas und einer flüssigkeit, sowie verfahren und vorrichtung zu seiner herstellung |
US7196164B2 (en) * | 1997-07-08 | 2007-03-27 | Human Genome Sciences, Inc. | Secreted protein HHTLF25 |
US6861227B2 (en) * | 1998-03-19 | 2005-03-01 | Human Genome Sciences, Inc. | Antibodies to cytokine receptor common gamma chain like |
JP2004529090A (ja) * | 2001-02-01 | 2004-09-24 | ハイドロン テクノロジーズ,インク. | 組織に酸素を供給する超酸素化組成物及び方法 |
US6902902B2 (en) * | 2001-11-27 | 2005-06-07 | Arena Pharmaceuticals, Inc. | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders |
US20060275199A1 (en) * | 2005-06-03 | 2006-12-07 | BAGLEY David | System for producing super-oxygenated and structured water |
EP3170401B1 (en) * | 2006-10-25 | 2019-06-05 | Revalesio Corporation | Ionic aqueous fluid composition containing oxygen microbubbles |
WO2008052145A2 (en) * | 2006-10-25 | 2008-05-02 | Revalesio Corporation | Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution |
US20080154795A1 (en) * | 2006-12-25 | 2008-06-26 | Amos Alon | Auction platform and applications |
JP2008156320A (ja) * | 2006-12-26 | 2008-07-10 | Hydrox Kk | 抗酸化性機能水 |
AU2008316794B2 (en) * | 2007-10-25 | 2015-04-23 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
US20090227018A1 (en) * | 2007-10-25 | 2009-09-10 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
-
2010
- 2010-04-27 JP JP2012508605A patent/JP2012525396A/ja active Pending
- 2010-04-27 MX MX2011011333A patent/MX2011011333A/es active IP Right Grant
- 2010-04-27 BR BRPI1013992A patent/BRPI1013992A2/pt active Search and Examination
- 2010-04-27 EP EP10770213A patent/EP2424507A4/en not_active Withdrawn
- 2010-04-27 AU AU2010241736A patent/AU2010241736B2/en not_active Ceased
- 2010-04-27 WO PCT/US2010/032620 patent/WO2010126908A1/en active Application Filing
- 2010-04-27 CN CN201080018429.3A patent/CN102413817B/zh not_active Expired - Fee Related
- 2010-04-27 CA CA2758738A patent/CA2758738A1/en not_active Abandoned
-
2011
- 2011-10-25 IL IL215925A patent/IL215925A0/en unknown
-
2015
- 2015-08-31 JP JP2015170249A patent/JP2015229678A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2010241736A1 (en) | 2011-12-22 |
CN102413817B (zh) | 2014-12-17 |
AU2010241736B2 (en) | 2016-01-28 |
CN102413817A (zh) | 2012-04-11 |
CA2758738A1 (en) | 2010-11-04 |
WO2010126908A1 (en) | 2010-11-04 |
IL215925A0 (en) | 2011-12-29 |
JP2015229678A (ja) | 2015-12-21 |
EP2424507A4 (en) | 2012-10-24 |
JP2012525396A (ja) | 2012-10-22 |
BRPI1013992A2 (pt) | 2016-08-16 |
EP2424507A1 (en) | 2012-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011011333A (es) | Composiciones y metodos para tratar la resistencia a la insulina y la diabetes mellituscampo de la invencion. | |
MX337862B (es) | Composiciones y métodos para el tratamiento de la esclerosis multiple. | |
WO2009134929A3 (en) | Compositions and methods for treating digestive disorders | |
MX2010004554A (es) | Composiciones y métodos para el tratamiento de inflamación. | |
MX2013001636A (es) | Composiciones y metodos para el tratamiento de taupatias | |
EA201170601A1 (ru) | Модуляторы регулятора трансмембранной проводимости при муковисцидозе | |
BR112014010275A2 (pt) | formulações para tratamento de diabetes | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
CO6210752A2 (es) | Compuestos biciclicos y uso como antidiabeticos | |
BR112012014575A2 (pt) | "uso combinado de proteínas cry1da e cry1fa para gerenciamento de resistência em inseto" | |
BRPI0910368B8 (pt) | uso de um ou mais biointensificadores, composição para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores e colírio para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores | |
BRPI0810874A2 (pt) | Líquido iônico, proceso para preparar um líquido iônico, e, uso de líquidos iônicos. | |
ATE548677T1 (de) | Ionische flüssigkeit | |
EA201270802A1 (ru) | Димерные слитые белки vstm3 и связанные с ними композиции и способы | |
BR112015013809A2 (pt) | derivados de exendina-4 como agonistas duplos de glp1/gip ou trigonais de glp1/gip/lucagon, seu uso e composição farmacêutica | |
BR112014018575A2 (pt) | polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) | |
WO2008057930A3 (en) | Methods of treating neuropathic pain with retinoic acid receptor agonists | |
WO2008027420A3 (en) | Implantable devices for producing insulin | |
TW200712059A (en) | Ionic liquids of low viscosity | |
NI201200134A (es) | Polipéptidos agonistas que se enlazan a dr5 | |
DE602006012532D1 (de) | Zellfreie in-vitro-transkription und translation von membranproteinen in gebundene planare lipidschichten | |
ECSP066777A (es) | Derivados de furosemida como moduladores de hm74 y su uso para el tratamiento de inflamacion | |
ITMI20080570A1 (it) | Procedimento per la preparazione di polibutadiene ramificato ad alto contenuto in unita' 1,4-cis | |
ATE453650T1 (de) | Salze mit alkoxytris(fluoralkyl)borat-anionen | |
RU2010145968A (ru) | Антиэймериозная фармацевтическая композиция на основе соли четвертичного фосфония и замещенного динитробензофуроксана |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |